85 results
8-K
EX-99.1
KALV
KalVista Pharmaceuticals Inc
11 Mar 24
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
4:37pm
for the three months ended January 31, 2024, or January 31, 2023.
R&D Expenses: Research and development expenses were $22.5 million for the three months … research and development.
Cash Position: Cash, cash equivalents and marketable securities were $75.6 million as of January 31, 2024, compared
424B5
KALV
KalVista Pharmaceuticals Inc
16 Feb 24
Prospectus supplement for primary offering
4:29pm
subsequently received a payment related to a U.K. government research and development tax credit program of approximately $16.6 million in cash … the sale of securities under this prospectus for general corporate purposes, which may include funding research and development, increasing our working
424B5
KALV
KalVista Pharmaceuticals Inc
14 Feb 24
Prospectus supplement for primary offering
5:13pm
subsequently received a payment related to a U.K. government research and development tax credit program of approximately $16.6 million in cash. The actual … proceeds from the sale of securities under this prospectus for general corporate purposes, which may include funding research and development
8-K
EX-99.1
KALV
KalVista Pharmaceuticals Inc
7 Dec 23
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
4:17pm
for the three months ended October 31, 2023, or October 31, 2022.
R&D Expenses: Research and development expenses were $19.1 million for the three months … in operating expenses, primarily research and development.
Cash Position: Cash, cash equivalents and marketable securities were $103.2 million
8-K
EX-99.1
e07gppbju76f77j
7 Sep 23
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
4:35pm
8-K
EX-99.1
5tju40p6mynahtf wi
7 Jul 23
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
7:10pm
S-8
EX-99.1
ms7zbm5 grg
20 Jun 23
Registration of securities for employees
4:13pm
424B5
p3rqfemu6r 9lxj
27 Dec 22
Prospectus supplement for primary offering
5:12pm
8-K
EX-99.1
z0tvqk0y
8 Dec 22
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
4:13pm
8-K
EX-99.1
fn3znaxd40 b5fwx
8 Sep 22
KalVista Pharmaceuticals Reports First Fiscal Quarter Results
4:13pm
8-K
EX-99.1
sd0c261qocdja42vy
7 Jul 22
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
4:24pm